Gyre Therapeutics Inc.
Statements
Cash Flow
Gyre Therapeutics Inc. (GYRE) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -17 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.1 | -5.0 | -4.3 | -4.4 | -4.9 | -6.3 | -5.1 | -7.4 | -7.0 | -9.0 | -15 | -11 | -9.1 | -8.1 | -4.8 | -15 | -13 | -22 | -24 | -20 | -22 | -18 | 9.0 | -12 | -7.3 | 42 | 10 | 4.5 | 7.6 | 3.4 | 2.9 | -5.6 | 1.7 | -2.8 | -0.1 | 2.1 | 4.7 | -5.6 | 3.2 | -17 | -14 | |
| 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.5 | 0.1 | 0.0 | 0.0 | 0.3 | 0.3 | 0.2 | 0.3 | 0.4 | 0.2 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.7 | 0.7 | 1.5 | 3.5 | |
| 0.2 | 0.1 | 0.1 | 0.1 | 0.3 | 0.3 | 0.6 | 0.6 | 0.7 | 0.7 | 0.8 | 0.9 | 0.8 | 0.7 | 0.8 | 0.8 | 1.1 | 0.9 | 1.0 | 1.0 | 0.7 | 0.7 | 0.6 | 0.3 | 0.2 | 0.3 | 0.2 | 0.1 | 0.1 | 7.3 | 0.0 | 0.0 | 0.2 | 0.6 | 0.5 | 0.9 | 1.1 | 4.6 | 2.6 | 2.1 | 10 | |
| -0.5 | 0.8 | -0.3 | 1.3 | 0.5 | -0.9 | -0.8 | -1.5 | -0.1 | 1.0 | -0.7 | 1.4 | 2.8 | 4.8 | -1.6 | 1.3 | 1.9 | -4.2 | -3.0 | -1.2 | 2.8 | 1.9 | 0.8 | -7.1 | -2.8 | 0.4 | 6.0 | 0.7 | -0.6 | 1.5 | -2.8 | -7.4 | -1.9 | -3.6 | -3.3 | -0.3 | -2.5 | -9.5 | 9.5 | 4.6 | 2.2 | |
| 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.3 | 0.5 | 0.3 | 3.1 | 2.6 | 1.9 | 2.4 | 1.7 | 2.5 | 2.0 | 2.3 | 0.2 | 1.5 | 0.7 | 0.7 | 0.8 | 0.3 | 0.7 | 0.1 | 0.2 | 1.3 | 2.3 | |
| 2.4 | 5.8 | 6.8 | 0.0 | -16 | -1.5 | 0.8 | -73 | -3.6 | 4.2 | 8.7 | 3.7 | 15 | 0.4 | 27 | -24 | -21 | 28 | 28 | 11 | 7.0 | 2.9 | -3.1 | 53 | -1.3 | -69 | -7.6 | -8.1 | -5.4 | 1.3 | -7.2 | -8.3 | -2.4 | -2.0 | 2.0 | -3.0 | -1.2 | 1.8 | -3.1 | 9.8 | 7.3 | |
| – | – | – | – | – | 4.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 45 | 45 | 7.8 | 3.5 | 1.5 | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -0.1 | – | – | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.7 | 0.1 | 1.8 | 22 | -0.3 | -3.0 | 111 | 0.0 | – | 0.1 | 0.1 | 0.1 | 0.1 | – | 32 | 28 | -0.1 | – | 49 | 0.0 | 0.1 | – | -0.1 | -0.1 | -45 | 45 | -7.8 | -3.5 | -1.5 | 2.5 | 0.7 | 0.3 | 0.4 | 1.0 | 1.3 | 22 | 0.4 | 0.3 | 0.0 | 0.0 | 0.7 | |
| -2.0 | 0.9 | 4.3 | 18 | -21 | 3.5 | 107 | -80 | -11 | -4.8 | -6.2 | -7.7 | 5.6 | -7.6 | 55 | -11 | -34 | 5.4 | 53 | -9.4 | -14 | -15 | 5.7 | 41 | -52 | 2.1 | -14 | -4.4 | 2.4 | 7.4 | -3.7 | -14 | -0.2 | -4.1 | 3.2 | 21 | 3.9 | -3.3 | 0.4 | 5.8 | 6.8 | |
| -5.1 | -5.1 | -4.3 | -4.4 | -4.9 | -6.3 | -5.3 | -7.4 | -7.0 | -9.2 | -15 | -12 | -9.1 | -8.1 | -4.8 | -15 | -13 | -22 | -24 | -20 | -22 | -18 | 5.9 | -15 | -7.3 | 40 | 8.7 | 2.1 | 5.6 | 1.0 | 2.7 | -7.1 | 1.0 | -3.5 | -1.0 | 1.8 | 4.0 | -5.8 | 3.0 | -18 | -17 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.